Rozanolixizumab

罗泽利昔珠单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameRozanolixizumab
Drug Alias NameRozanolixizumab-NOLI洛利昔珠单抗罗泽利昔珠RYSTIGGO优迪革 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsIgG receptor FcRn large subunit p51 antagonists
TargetsIgG receptor FcRn large subunit p51
Therapy Area/IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseasePurpura, Thrombocytopenic, IdiopathicEncephalitis +[6] 
Global Approved IndicationsMyasthenia Gravis
Approved Indications in ChinaMyasthenia Gravis
Original Approved Country/TerritoryUnited States
Original Approved Date2023/06/27
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcb Sa
China Registration ClassN/A

Develop Information

Active CompaniesUcb Biopharma SrlUcb IncUcb Pharma +[7] 
Inactive CompaniesUcb CelltechUcb Biopharma SprlVetter Pharma-Fertigung Gmbh & Co Kg
Active IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseasePurpura, Thrombocytopenic, IdiopathicPolyradiculoneuropathy, Chronic Inflammatory Demyelinating +[5] 
Inactive IndicationsEncephalitis

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG